The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
The expansion makes Exothera one of the largest viral vector facilities in Europe
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Collaboration in the industry needs to be institutionalised to drive the growth.
Subscribe To Our Newsletter & Stay Updated
